Articoli 2011-2007

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+. (Sacchi V. - Farmeconomia e percorsi terapeutici 2011; 12(2): 77-85)

Cost-effectiveness evaluations of spinal neuromodulation with ziconotide continuous infusion in cancer pain in a real clinical practice. (Zaniolo O, Iannazzo S, Patrucco GP, Bellini R. - Farmeconomia e percorsi terapeutici 2011; 12(2): 87-94)

Tiotropium bromide in the routine care of GOLD stage II COPD patients: a pharmaeconomic evaluation. (Zaniolo O, Carsi M, Iannazzo S. - Farmeconomia e percorsi terapeutici 2011; 12(2): 45-52)

Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice. (Zaniolo O, Bettoncelli G, Bosio G, Mantovani L, Pistelli R, Vaghi A, Villa M, Iannazzo S, Bamfi F, Frizzo V, Dal Negro RW. - Farmeconomia e percorsi terapeutici 2011; 12(1): 5-19)

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. (Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. - Eur Ann Allergy Clin Immunol 2011; 43(2): 45-53)

Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. (Iannazzo S, Pradelli L, Carsi M, Perachino M. - Value Health 2011; 14(1): 80-9)

Pharmacoeconomic evaluation of the MF59–adjuvanted influenza vaccine in the elderly population in Italy. (Iannazzo S. - J Prev Med Hyg 2011; 52(1):1-8)

Un modello di Budget Impact per la valutazione economica di tocilizumab come prima linea biologica nei pazienti con artrite reumatoide di grado moderato o severo. (Capri S, Benucci M, Iannazzo S, Zaniolo O, D’Arpino A. - Italian Journal of Public Health – Year 8, Volume 7, Number 2, Suppl 2, 2010: S44-53)

Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. (Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. - Pharmacoeconomics 2010; 28(11): 1041-54)

Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. (Benucci M, Iannazzo S, Zaniolo O, Sabadini L. - Clin Exp Rheumatol 2010; 28(5): 722-7)

Organization and Estimated Patient-Borne Costs of Oral Anticoagulation Therapy in Italy: Results from a Survey. (Pradelli L, Iannazzo S, Zaniolo O, Botrugno P. - Appl Health Econ Health Policy 2010; 8 (2): 119-128)

Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: Adaptation for Italy. (Zaniolo O, Wolowacz SE, Pradelli L. - Farmeconomia e percorsi terapeutici 2010; 11(2): 91-101)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept. (Sacchi V, Zaniolo O, Olivieri I. - Farmeconomia e percorsi terapeutici 2010; 11(2): 63-76)

Tiotropium in COPD: clinical outcomes and economic evidence. (Zaniolo O, Sacchi V, Dal Negro RW. - Farmeconomia e percorsi terapeutici 2010; 11(1): 27-41)

The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy: A Probabilistic Markov Model. (Pradelli L, Iannazzo S, Zaniolo O. - Am J Cardiovasc Drugs 2009; 9: 383-392)

Effectiveness and cost of treatment with maraviroc in HIV infection. (Sacchi V, Pradelli L. - Farmeconomia e percorsi terapeutici 2009; 10(4): 149-159)

Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery. (Zaniolo O. - Farmeconomia e percorsi terapeutici 2009; 10(3): 115-128)

Sugammadex in antagonism of neuromuscular block in anesthesia: a clinical and economic profile. (Sacchi V, Iannazzo S, Giunta F. - Farmeconomia e percorsi terapeutici 2009; 10(3): 103-114)

The clinical and economic value of the dipeptide alanyl-glutamine in total parenteral nutrition of critically ill patients treated in intensive care units in Italy. (Muscaritoli M, Pradelli L, Zaniolo O, Iannazzo S, Eandi M. - Farmeconomia e percorsi terapeutici 2009; 10(2): 83-92)

Costs of diabetes in Italy. (Zaniolo O. - Farmeconomia e percorsi terapeutici 2009; 10(2): 73-81)

Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy. (Iannazzo S, Sacchi V. - Farmeconomia e percorsi terapeutici 2009; 10(2): 59-72)

Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. (Pradelli L, Iannazzo S. - Journal of Medical Economics 2009; 12(1): 25-35)

Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy. (Bamfi F, Basso F, Aglietta M, Bengala C, Lorusso V, Pronzato P, Cavallo MC, Zaniolo O, Iannazzo S. - Farmeconomia e percorsi terapeutici 2009; 10(1): 33-46)

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy. (Benucci M, Iannazzo S, Sabadini L. - Farmeconomia e percorsi terapeutici 2009; 10(1): 19-31)

Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System. (Zaniolo O, Pradelli L. - Farmeconomia e percorsi terapeutici 2009; 10(1): 5-18)

Maraviroc (Celsentri) in HIV treatment. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(4): 219-222. Edited by AdRes Health Economics & Outcomes Research)

Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(4): 215-218. Edited by AdRes Health Economics & Outcomes Research)

Usefulness and limitation of DDD and PDD analyses. 12 months of solid oral antipsychotics prescribing data for the NHS-reimbursed treatment of schizophrenia in Italy. (Pradelli L. - Farmeconomia e percorsi terapeutici 2008; 9(4): 191-196)

Daptomycin (Cubicin) in patients with complicated skin or soft-tissue infections. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(3): 163-166. Edited by AdRes Health Economics & Outcomes Research)

Entecavir (Baraclude) in patients with chronic hepatitis B virus (HPV) infection. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(3): 157-161. Edited by AdRes Health Economics & Outcomes Research)

Cost-efficacy analysis of hormonal treatments for advanced prostate cancer. (Iannazzo S, Pradelli L. - Farmeconomia e percorsi terapeutici 2008; 9(3): 147-156)

Budget impact of vildagliptin. (Zaniolo O, Sacchi V, Pradelli L. - Farmeconomia e percorsi terapeutici 2008; 9(3): 137-146)

Pharmacoeconomic analysis of valsartan for the treatment of chronic congestive heart failure in Italy. (Iannazzo S, Pradelli L, Zaniolo O. - Farmeconomia e percorsi terapeutici 2008; 9(3): 125-135)

Rotigotine patches (Neupro) in early Parkinson’s disease. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(2): 115-119. Edited by AdRes Health Economics & Outcomes Research)

Natalizumab (Tysabri) in multiple sclerosis patients. (Sacchi V. - Farmeconomia e percorsi terapeutici 2008; 9(2): 109-114. Edited by AdRes Health Economics & Outcomes Research)

Sartans: differences, similitudes and costs. (Zaniolo O, Iannazzo S. - Farmeconomia e percorsi terapeutici 2008; 9(2): 69-88)

Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis. (Iannazzo S, Pradelli L. - Farmeconomia e percorsi terapeutici 2008; 9(1): 5-14)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects. (Pradelli L, Eandi M. - umori 2008; 94: 26-32)

Parnaparin: review of the literature. (Pradelli L. -Farmeconomia e percorsi terapeutici 2008; 9(1): 27-40)

La schizofrenia: percorsi diagnostico-terapeutici e costo di malattia. (Zaniolo O, Pradelli L. - Profili in Farmacoeconomia 2008; 6)

Economic evaluation of treatment with orlistat in Italian obese patients. (Iannazzo S, Zaniolo O, Pradelli L. - Curr Med Res Opin 2008; 24(1): 63-74)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects. (Pradelli L, Eandi M. - Tumori 2008; 94: 26-32)

Profilo farmacologico, clinico ed economico dell’associazione fissa di beclometasone dipropionato e formoterolo in formulazione extra-fine nella terapia di pazienti con asma bronchiale. (Cremonesi G, Pradelli L. - Profili in Farmacoeconomia 2008; 7)

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. (Dal Negro RW, Eandi M, Pradelli L, Iannazzo S. - Int J Chron Obstruct Pulmon Dis 2007; 2(2): 169-176)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects. (Pradelli L, Eandi M. - Farmeconomia e percorsi terapeutici 2007; 8(2): 71-80)

Il disturbo bipolare: percorsi diagnostico-terapeutici e costo di malattia. (Zaniolo O, Pradelli L. - Profili in Farmacoeconomia 2007; 4)

Il costo dei disturbi ansiosi e depressivi e l’appropriatezza del percorso diagnostico-terapeutico nel paziente afferente al medico di medicina generale. (Siracusano A, Niolu C, Pradelli L. - Profili in Farmacoeconomia 2007; 4)

Profilo farmacologico clinico di paroxetina. (Siracusano A, Niolu C, Pradelli L. - Profili in Farmacoeconomia 2007; 4)

Bayesian statistic methods and theri application in probabilistic simulation models. (Iannazzo S. - Farmeconomia e percorsi terapeutici 2007; 8(1): 5-13)

Problematiche relative ai criteri auxologici nella diagnosi di bassa statura da deficit di GH e prescrizione dell’ormone della crescita ricombinante. (Gilli G, Benso L, Pradelli L. -Clinical Management Issues 2007; 1: 165-170)

Trattamento delle infezioni vaginali in gravidanza con metronidazolo e clotrimazolo topici. (Pradelli L. - Clinical Management Issues 2007; 1(1): 21-29)

Pay-back direct to Regions: a new possibility for companies. (Zaniolo O. - Farmeconomia e percorsi terapeutici 2007; 8(1): 47-48)

Simvastatin: between clinics and health economics. (Costa FV, Zaniolo O. - Farmeconomia e percorsi terapeutici 2007; 8(1): 27-45)

Budget impact of rosiglitazone in type 2 diabetes. (Zaniolo O, Bamfi F, Iannazzo S. - Farmeconomia e percorsi terapeutici 2007; 8(1): 15-26)